ZA200705040B - 2,4 (4,6) pyrimidine derivatives - Google Patents

2,4 (4,6) pyrimidine derivatives

Info

Publication number
ZA200705040B
ZA200705040B ZA200705040A ZA200705040A ZA200705040B ZA 200705040 B ZA200705040 B ZA 200705040B ZA 200705040 A ZA200705040 A ZA 200705040A ZA 200705040 A ZA200705040 A ZA 200705040A ZA 200705040 B ZA200705040 B ZA 200705040B
Authority
ZA
South Africa
Prior art keywords
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
ZA200705040A
Other languages
English (en)
Inventor
Eddy Jean Edgar Freyne
Werner Constant Johan Embrechts
Brandt Sven Franciscus Anna Van
Marc Willems
Emelen Kristof Van
Frederik Jan Rita Rombouts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA200705040B publication Critical patent/ZA200705040B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA200705040A 2004-12-08 2007-06-07 2,4 (4,6) pyrimidine derivatives ZA200705040B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63429104P 2004-12-08 2004-12-08
EP04106384 2004-12-08

Publications (1)

Publication Number Publication Date
ZA200705040B true ZA200705040B (en) 2008-09-25

Family

ID=34930016

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705040A ZA200705040B (en) 2004-12-08 2007-06-07 2,4 (4,6) pyrimidine derivatives

Country Status (23)

Country Link
US (2) US8148388B2 (es)
EP (1) EP1824856B1 (es)
JP (1) JP5022909B2 (es)
KR (1) KR101428506B1 (es)
CN (1) CN101072779B (es)
AR (1) AR051788A1 (es)
AU (1) AU2005313348B2 (es)
BR (1) BRPI0518424B8 (es)
CA (1) CA2588761C (es)
CR (1) CR9234A (es)
DK (1) DK1824856T3 (es)
EA (1) EA013368B1 (es)
ES (1) ES2442458T3 (es)
HK (1) HK1112455A1 (es)
IL (1) IL183706A0 (es)
MX (1) MX2007006821A (es)
MY (1) MY169441A (es)
NO (1) NO340130B1 (es)
NZ (1) NZ554820A (es)
TW (1) TWI374140B (es)
UA (1) UA90693C2 (es)
WO (1) WO2006061415A1 (es)
ZA (1) ZA200705040B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83881C2 (en) 2003-12-18 2008-08-26 Янссен Фармацевтика Н.В. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
EP1797050B1 (en) * 2004-08-10 2013-10-23 Janssen Pharmaceutica NV Hiv inhibiting 1.2.4-triazin-6-one derivates
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
ATE469158T1 (de) 2005-11-16 2010-06-15 S Heteroalkylgebundene pyrimidinderivate
JP2009542778A (ja) 2006-07-13 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Mtkiキナゾリン誘導体
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
DK2185562T3 (en) 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
CA2702674C (en) 2007-10-19 2016-05-03 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
JP5480824B2 (ja) 2008-03-10 2014-04-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Plkキナーゼ阻害剤としての4−アリール−2−アニリノ−ピリミジン
CA2722326A1 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2735420C (en) 2008-09-08 2016-06-28 Merck Patent Gmbh Macrocyclic pyrimidines as protein kinase inhibitors
US8765727B2 (en) 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ttk阻害作用を有するピリジンおよびピリミジン誘導体
AU2011254550B2 (en) 2010-05-21 2013-11-07 Noviga Research Ab Novel pyrimidine derivatives
MX2013004894A (es) 2010-11-01 2013-10-17 Celgene Avilomics Res Inc Compuestos heterociclicos y usos de los mismos.
EP2646448B1 (en) * 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
CA2866852C (en) 2012-03-15 2020-12-29 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
CA2911259A1 (en) * 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) * 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
BR112017013677B1 (pt) * 2015-02-05 2023-11-21 Merck Patent Gmbh Compostos macrocíclicos como inibidores de irak1/4, seu processo de fabricação e seus usos, e composições farmacêuticas
CA3057892A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
EP3601236A1 (en) * 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
BR112021024874A2 (pt) 2019-06-12 2022-01-25 Nouryon Chemicals Int Bv Processo para a produção de peróxidos de diacila
HUE063796T2 (hu) 2019-06-12 2024-01-28 Nouryon Chemicals Int Bv Eljárás diacil-peroxidok elõállítására
US20220306490A1 (en) * 2019-06-12 2022-09-29 Nouryon Chemicals International B.V. Method for isolating carboxylic acid from an aqueous side stream
CA3171185A1 (en) * 2020-02-14 2021-08-19 Salk Institute For Biological Studies Macrocyclic ulk1/2 inhibitors
CN113549113A (zh) * 2020-06-17 2021-10-26 广州百霆医药科技有限公司 一种含膦大环化合物及其制备方法与应用
KR102613509B1 (ko) * 2021-12-15 2023-12-13 환인제약 주식회사 마크로사이클릭 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신경 퇴행성 질환의 예방 또는 치료용 약학적 조성물
WO2023113510A1 (ko) * 2021-12-15 2023-06-22 환인제약 주식회사 마크로사이클릭 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신경 퇴행성 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523497A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
CN103169708B (zh) * 2002-07-29 2018-02-02 里格尔药品股份有限公司 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
PA8603801A1 (es) 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
UA83881C2 (en) 2003-12-18 2008-08-26 Янссен Фармацевтика Н.В. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
CN1893944B (zh) 2003-12-18 2011-07-06 詹森药业有限公司 具有抗增殖活性的3-氰基喹啉衍生物

Also Published As

Publication number Publication date
US8148388B2 (en) 2012-04-03
AU2005313348B2 (en) 2011-10-06
MX2007006821A (es) 2007-07-24
EA013368B1 (ru) 2010-04-30
NO20073492L (no) 2007-07-09
ES2442458T3 (es) 2014-02-11
EP1824856A1 (en) 2007-08-29
NZ554820A (en) 2010-10-29
CA2588761A1 (en) 2006-06-15
TW200635931A (en) 2006-10-16
TWI374140B (en) 2012-10-11
AU2005313348A1 (en) 2006-06-15
BRPI0518424B8 (pt) 2021-05-25
MY169441A (en) 2019-04-11
KR101428506B1 (ko) 2014-08-12
AR051788A1 (es) 2007-02-07
CA2588761C (en) 2015-04-21
CR9234A (es) 2008-09-09
EP1824856B1 (en) 2013-10-23
CN101072779A (zh) 2007-11-14
IL183706A0 (en) 2007-09-20
UA90693C2 (en) 2010-05-25
BRPI0518424B1 (pt) 2020-10-13
KR20070085438A (ko) 2007-08-27
DK1824856T3 (da) 2014-01-27
US8394955B2 (en) 2013-03-12
NO340130B1 (no) 2017-03-13
WO2006061415A1 (en) 2006-06-15
JP5022909B2 (ja) 2012-09-12
US20100160310A1 (en) 2010-06-24
HK1112455A1 (es) 2008-09-05
BRPI0518424A2 (pt) 2008-11-25
EA200701245A1 (ru) 2007-12-28
JP2008523033A (ja) 2008-07-03
US20120065395A1 (en) 2012-03-15
CN101072779B (zh) 2010-12-22

Similar Documents

Publication Publication Date Title
IL183706A0 (en) 2,4(4,6) pyrimidine derivatives
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
HK1091488A1 (en) Pyrimidine derivatives
IL181433A0 (en) Pyrimidine derivatives
IL181386A0 (en) Pyrimidine derivatives
SI1487805T1 (sl) Pirimidinski derivati
MX267068B (es) Derivados simetricos de triazina.
GB0415364D0 (en) Pyrimidine derivatives
IL179914A0 (en) Pyrimidine derivatives
AP2005003198A0 (en) Spiroindolinepiperidine derivatives.
ZA200500170B (en) Indole-3-sulphur derivatives.
HK1090368A1 (en) 2,3,6-trisubstituted-4-pyrimidone derivatives
EP1724267A4 (en) PYRIMIDINE DERIVATIVE
IL182099A0 (en) Piperidinylamino-thieno[2,3-d] pyrimidine compounds
HK1086012A1 (en) 8-substitued-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives
HK1088893A1 (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives
AP2005003403A0 (en) Substituted pyrimidinones.
AP2008004486A0 (en) Pyrimidine derivatives
GB0525080D0 (en) Pyrimidine derivatives
GB0525083D0 (en) Pyrimidine derivatives
SI1869056T1 (sl) Novi 5-substituirani 7-amino-(1,3)tiazolo(4,5-d) pirimidinski derivati
ZA200506744B (en) PyrazoloÄ1,5-AÜpyrimidine derivatives
IL183140A0 (en) Substituted benzoquinolizine derivatives
GB0525081D0 (en) Pyrimidine derivatives
EP1830858A4 (en) 3,6-BICYCLOLIDE